New directions in anticoagulant and antiplatelet treatment

The advent of two new classes of drugs, the thrombin inhibitors and the IIB/IIIa platelet receptor blockers, may lead to major changes in anticoagulation practice the coming decade. We review the currently available data from clinical studies and speculate on how these classes of drugs may come to be used in clinical practice, bearing in mind that the benefits of these classes of drugs have not yet been determined precisely.

Thrombin inhibitors
The development of a thrombus, initiated by the formation of thrombin as the final stage of the coagulation cascade, is the major triggering mechanism in many acute ischaemic syndromes. Thrombin formation has three major effects:

- Generation of more thrombin through a positive feedback loop
- Formation of fibrin
- Activation of thrombocytes leading to aggregation and release of various vasoconstrictive and procoagulant factors.

Specific thrombin inhibitors block these effects, thus preventing or reducing both fibrin formation and thrombocyte aggregation (figure). The new generation of thrombin inhibitors include direct derivatives of hirudin, isolated from the leech Hirudo medicinalis, such as recombinant hirudin (a 65 amino acid polypeptide) and hirulog (a 20 amino acid peptide) as well as other synthetic compounds, including hirugen, argatroban, and efegatran.

Though the thrombin inhibitors are often compared to heparin and like heparin can be given intravenously or subcutaneously, their mechanism of action is quite different. Heparin inhibits thrombin formation, but its pharmacological activity is less specific than that of these new drugs. Among other factors, heparin requires antithrombin III, and it cannot inactivate clot-bound thrombin. Heparin can be inactivated by plasma proteins and platelet factor 4, and it has other effects in addition to its anticoagulant properties, including inhibition of platelet function and inhibition of proliferation of vascular smooth muscle cells. In contrast, the new compounds are specific direct inhibitors of both free and clot-bound thrombin.

Heparin can be neutralised with protamine sulphate, but as yet the specific thrombin inhibitors have no antidote. Accordingly, this new class of drugs may be less suitable when the anticoagulation effect needs to be rapidly reversed—for example, during cardiac surgery. Nevertheless, the longest acting thrombin inhibitors have a half life of no more than a few hours, and when the infusion of the drug is stopped normal coagulation is quickly restored.

It is not certain how the optimal dose of specific thrombin inhibitors should be determined. Heparin dosing is adjusted according to measurement of activated partial thromboplastin time (aPTT) or activated clotting time (ACT). The thrombin inhibitors also prolong these indices in a steep, dose dependent manner, that could result in high levels of anticoagulation after even a small increase in dose. We do not know whether the same prolongation of aPTT or ACT in patients treated with antithrombins represents the same level of anticoagulation and clinical efficacy as when they are treated with heparin. More data are needed to establish the relation between the desired clinical effects and the laboratory indices. No significant side effects were seen in 291 patients undergoing angioplasty who were treated with four different doses of hirulog, and there were no bleeding complications even at the highest dosage. In direct comparative trials of heparin and recombinant hirudin in patients undergoing percutaneous transluminal coronary angioplasty (PTCA), infusion of hirudin (CGP 39393) was associated with higher and more stable aPTT measurements.

Preliminary evidence suggests that hirudin is a more effective anticoagulant than heparin in patients with unstable angina undergoing PTCA. The risk of early serious complications (death, myocardial infarction, or revascularisation) was about 40% less in the 759 patients treated with hirudin than in the 382 treated with heparin, though little difference was observed between the three regimes (two hirudin and one heparin regimen) at 6 months follow up. The risk of bleeding associated with the specific inhibitor seemed to be slight and the number of acute thrombotic complications small. Nevertheless, the efficacy and safety of the specific thrombin inhibitors should be assessed in larger trials and in more diverse clinical conditions. The concomitant administration of the thrombin inhibitors and thrombolytic agents needs careful consideration, and special attention should be given to the selection of the optimal dose under such circumstances. Initial experience with hirudin in combination with alteplase and with strep-
tokinase revealed no major safety issues. However, in three subsequent larger studies an excess of major bleeding, in particular intracranial bleeds, was seen in patients treated with a high dose of hirudin combined with thrombolytic treatment (table 1). The overall rate of intracranial haemorrhage with hirudin was 2.2%. Other bleeding complications were also more frequent in patients receiving hirudin. Surprisingly, in two studies (GUSTO IIa and TIMI 9A) an unexpected excess of intracranial haemorrhage was also seen in patients receiving heparin in combination with thrombolytic treatment. This illustrates the narrow therapeutic range of combined thrombolytic and anticoagulant treatment. In fact, the heparin dosages in GUSTO IIa and TIMI 9A were only slightly higher than in previous studies. After extensive consultation two trials have been restarted—GUSTO IIb and TIMI 9B—both with a more prudent heparin regimen, and with a much lower dose of hirudin, which was reduced from a bolus of 0-6 mg/kg and an infusion of 0-2 mg/kg/h to a bolus of 0-1 mg/kg followed by an infusion of 0-1 mg/kg/h. Another option might have been to reduce the dose of the thrombolytic agent, and further studies are needed to determine the optimal dosages for combination treatment in patients with evolving myocardial infarction.

If the results of ongoing trials with hirudin and with other thrombin inhibitors are favourable, it is likely that the specific inhibitors will replace heparin for many indications, provided that their costs are not prohibitive. The current generation of specific thrombin inhibitors must be given parenterally. It is, however, possible that synthetic thrombin inhibitors will be developed for oral use. This would open the possibility for long-term use for indications like those for the current coumadin type oral anticoagulants.

### IIb/IIIa receptor blockers

Thrombocyte aggregation can be induced by many different stimuli, most commonly as a consequence of damage to the vessel wall. Platelets adhere to the vessel wall and are activated by the subendothelial tissue, notably collagen (figure), thereby inducing several coagulation reactions that result in thrombin generation, with the results described above. The final common pathway of platelet activation and aggregation is stimulation and activation of the thrombocyte glycoprotein (GP) IIb/IIIa receptor. This receptor complex consists of two interacting subunits, alpha and beta, belonging to the so-called integrin superfamily of adhesion receptors. Platelets aggregate as a result of (mainly) fibrinogen bridges between the IIb/IIIa receptors of adjacent thrombocytes. Several specific IIb/IIIa receptor blockers have been developed, including the chimeric 7E3 antibody (c7E3 Fab). Other inhibitors of thrombocyte aggregation block different pathways in the thrombocytes. For example, aspirin blocks the arachidonic acid pathway and specific inhibitors of thromboxane synthesis and/or thromboxane receptors have also been developed. Aspirin is used widely as a mild inhibitor of thrombocyte aggregation, but clinical studies with thrombocyte receptor blockers have been unsuccessful. In addition to the monoclonal antibodies to the IIb/IIIa receptor, smaller molecules including peptides (such as integrelin and MK-0852) and non-peptides (such as MK-0383 and RO 44-9883) are also being investigated in clinical trials. These smaller molecules may be an advantage in the clinical environment, in that their action may be more readily reversible with little or no antiplatelet activity.

So far, the monoclonal antibody c7E3 Fab has been tested most intensely, and its action has been studied in patients with refractory unstable angina, as well as during so-called high risk percutaneous transluminal coronary angioplasty. Sixty patients with angina at rest despite treatment with intravenous glyceryl trinitrate and heparin were randomised to (additional) c7E3 Fab or placebo given as a bolus injection followed by a 24 h infusion before angioplasty. After treatment with c7E3 Fab binding of the free platelet receptor decreased sharply within a few hours, whereas platelet aggregation gradually recovered within 48 hours of the end of c7E3 infusion. Patients who were given c7E3 Fab were less likely to have recurrent ischemia (9 of 16 patients) and more likely to have successful PTCA procedure (17% vs 30% failure). The risk of bleeding was similar in both groups (in 3 and 2 patients). In the much larger EPIC study, 2099 patients scheduled to undergo angioplasty and considered to be at high risk of abrupt vessel closure (and at low risk for bleeding) were given bolus of c7E3 Fab, a bolus and an infusion of c7E3 Fab, or placebo. Ischaemic complications associated with subsequent PTCA (chiefly non-fatal myocardial infarction and the need for emergency revascularisation) were reduced by 35% in the groups given c7E3, albeit against an increase in the risk of bleeding and a doubling of the transfusion rate (table 2). The efficacy of treatment persisted for 6 months. Ongoing trials must assess whether c7E3 and similar compounds will be as useful for other forms of arterial thrombosis including transient ischaemic attacks, stroke, and peripheral vascular disease.

The number of IIb/IIIa binding sites on the thrombocytes that are blocked and inhibition of platelet aggregation are affected by the dosage given. The current trials with c7E3 Fab aim at a dose that blocks more than 90% of

### Table 1 Intracranial haemorrhages in three recently published studies of heparin and hirudin combined with thrombolytic treatment

<table>
<thead>
<tr>
<th>Trial</th>
<th>Heparin (n%)</th>
<th>Hirudin (n%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GUSTO IIa</td>
<td>4/436 (0-9)</td>
<td>8/460 (1-7)</td>
</tr>
<tr>
<td>Alteplase</td>
<td>5/189 (2-7)</td>
<td>6/189 (3-2)</td>
</tr>
<tr>
<td>Streptokinase</td>
<td>3/150 (1.5)</td>
<td>4/144 (2-2)</td>
</tr>
<tr>
<td>TIMI 9A</td>
<td>7/368 (1-8)</td>
<td>8/368 (1-7)</td>
</tr>
<tr>
<td>HIT-III †</td>
<td>1/154 (0-6)</td>
<td>4/148 (2-7)</td>
</tr>
<tr>
<td>Total</td>
<td>17/1142 (1-5)</td>
<td>24/1137 (2-2)</td>
</tr>
</tbody>
</table>

* In GUSTO IIa 10 patients (5 heparin, 5 hirudin) received alteplase as well as streptokinase.
† All patients in HIT-III received alteplase.
‡ GUSTO, global use of strategies to open occluded coronary arteries; HIT, hirudin for improvement of thrombolysis; TIMI, thrombolysis in myocardial infarction.

### Table 2 Outcome (%) in EPIC with c7E3 Fab in 2099 patients undergoing "high risk" angioplasty

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Placebo</th>
<th>c7E3 Fab bolus</th>
<th>c7E3 Fab bolus + IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>696</td>
<td>695</td>
<td>708</td>
</tr>
<tr>
<td>Balloon angioplasty</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Atherectomy</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Both</td>
<td>5</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Major groin bleeding</td>
<td>2-8</td>
<td>7-9</td>
<td>8-1</td>
</tr>
<tr>
<td>Major other bleeding</td>
<td>3-7</td>
<td>3-9</td>
<td>5-8</td>
</tr>
<tr>
<td>Transfusions:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red cells</td>
<td>7-0</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>Platelets</td>
<td>3</td>
<td>4</td>
<td>6</td>
</tr>
</tbody>
</table>

30 days:
- Death: 1-7
- Non-fatal myocardial infarction: 8-6
- Emergency CABG: 3-6
- Emergency PTCA: 4-5
- Stent placement: 0-6

6 months:
- Death: 3-4
- Non-fatal myocardial infarction: 10-5
- CABG: 8-9
- Repeat PTCA: 20-9

EPIC, Evaluation of 7E3 for Prevention of Ischaemic Complications.
the platelet binding sites. However, there is uncertainty about whether this represents the optimal dose. Perhaps different levels of inhibition of platelet aggregation are appropriate for different indications, but this remains to be established. Such individualised treatment would require monitoring of the level of blockage of IIb/IIIa receptors, but currently there are no methods for such monitoring.

Previously, IIb/IIIa receptor blockers are available for intravenous use only, and their use is therefore restricted to patients in hospital. Oral compounds are being developed. If these were successful, they might replace aspirin for the long-term treatment of coronary artery disease, provided that they did not cost too much.

**Combined application**

Potentiation between thrombin inhibitors and IIb/IIIa receptor blockers has been seen in animal experiments. A combination of these compounds may become the preferred treatment. Similarly, in animal experiments thrombolysis was enhanced by addition of an IIb/IIIa receptor blocker to thrombocyte agents. Because such combinations could induce excessive bleeding careful studies are needed to determine the optimal dose combinations of these drugs for various groups of patients.

Different types of patients may need different approaches. In particular decisions on the level of anticoagulation or a decision to combine specific antithrombins with the IIb/IIIa receptor blockers might be based on the expected thrombotic risk in each patient.

**Myocardial infarction**

The risk of mortality and other complications in patients with myocardial infarction can be estimated from baseline characteristics including elderly age, a history of previous infarction, a large area at risk, and the presence of heart failure. Both the short and long-term benefits of thrombolytic treatment are directly proportional to the level of the baseline risk. Thus more intense treatment may be warranted in patients at a higher risk of mortality. In such patients, a combination of thrombolytic treatment with specific thrombin inhibitors and IIb/IIIa receptor blocker may be appropriate, even if such combination carries a higher bleeding risk. On the other hand, in subgroups of patients at low risk in whom the benefit of treatment is expected to be small, bleeding risk should be reduced and the mode and intensity of anticoagulant treatment should be adapted accordingly.

**Unstable angina**

Patients with unstable angina are at an increased risk of myocardial infarction and death. The term “unstable angina”, however, encompasses a wide range of disease with different levels of risks. The risk of complications is often over-rated, however. In 15 observational studies and randomised trials conducted in the 1970s and 1980s, before intravenous glyceryl trinitrate, heparin, and aspirin were widely used, average mortality was only 2% at one month and 6% at 6 months. In a more recent prospective registry of 282 patients with documented unstable angina (pain and electrocardiographic changes in hospital), non-fatal myocardial infarction developed in only 10% of the patients. Similarly, less than 10% of patients in the ATACS trial died or had non-fatal infarction.

In patients with unstable angina, in particular those at highest risk (for instance in patients with a recent (<24 hours) episode of ischaemia or in patients whose symptoms persist despite treatment) anticoagulant treatment should be intensive and be continued until the ruptured plaque has healed, ideally for 3–7 days.

Patients with unstable angina are likely candidates for intervention. The risk of complications during PTCA and other coronary interventions is related to the clinical presentation of the patient as well as to the angiographic appearance of the coronary lesion. Again, more intensive treatment will be warranted in patients with unstable angina, and antithrombotic and anticoagulant treatment can be increased if thrombotic complications are seen during or after the procedure.

**Chronic ambulatory treatment**

Most patients in whom coronary artery disease has been diagnosed, particularly those with angina and survivors of myocardial infarction, are currently treated with aspirin. Although indirect evidence suggests that the coumadin agents may be more effective, at least in myocardial infarction survivors, most clinicians favour the much cheaper and easier to use heparin. Heparin is the most appropriate, and/or specific receptor blockers become available, these may be prescribed to prevent thrombotic complications in these patients, and also after cardiac surgery and in those with atrial fibrillation, deep venous thrombosis, pulmonary embolism, and after vascular surgery. Again, the intensity of treatment could be tailored to the expected rate of thrombotic complications. More intensive treatment could be given in the first months after myocardial infarction or shortly after a period of unstable angina. Cigarette smoking, associated with activated coagulation, could also be considered as an indication for more intense coagulation. Treatment could be less intense in other circumstances, for instance during the first 6 months after an acute ischaemic event, and in elderly patients, who are at greater risk of bleeding complications.

**Conclusions**

The specific thrombin inhibitors and platelet IIb/IIIa receptor blockers that are currently being tested in clinical trials promise to provide better treatment for a wide range of patients at increased risk of thrombosis. Combination therapy may be appropriate, particularly when there are thrombotic complications, or in patients at greatest risk of complications. The most effective methods of monitoring the effect of these new treatments remain to be defined.

We thank Jean-Paul R Herman for preparing the figure.

Albelda SM, Coller 21

Lidén Topol EJ, Serruys 14

Antman 19

Neuhaus 9

Zoldhelyi 8


1994;23:344A.

1992. 5

1994;89:596-603.}


